Drug Profile
Otlertuzumab - Aptevo Therapeutics
Alternative Names: TRU-016Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Trubion Pharmaceuticals
- Developer Aptevo Therapeutics
- Class Antineoplastics; Monoclonal antibodies; Small molecules
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; CD37 protein inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
Most Recent Events
- 20 May 2021 Aptevo Therapeutics terminates a phase Ib trial for Chronic lymphocytic leukaemia (Combination therapy) and Peripheral T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV), as per business decision (NCT01644253)
- 14 Nov 2018 Discontinued - Phase-I for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in USA (IV)
- 14 Nov 2018 Discontinued - Phase-II for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in Austria (IV)